Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS: LNA043 in symptomatic knee osteoarthritis
2020-004897-22Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing LNA043 intra-articular regimen with Placebo intra-articular regimen (2 arms). Primary endpoint: Change from baseline in the knee structure. Started Apr 2021; status: terminated.
02
Drugs
LNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2020-004897-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004897-22.